14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BANX vs ACAD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, ArrowMark Financial Corp. (BANX) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (39.5/100 SELL vs. 44.8/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. BANX trades at $18.79 (14.6x Forward P/E, 75.4% operating margin) versus ACAD at $17.11 (15.8x Forward P/E, 10.2% operating margin).
Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. BANX 39.5/100 SELL), BANX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (75.4% vs. 10.2% operating margin) and revenue trajectory (-0.2% vs. +22.8% YoY).
Technical & Structure Timing Caution: BANX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BANX vs ACAD. Trailing 12-month operating profitability (BANX 75.4% vs ACAD 10.2%) and valuation multiples (BANX 14.6x vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment53.7% of Rev ($646M)
90D Engineering Disclosures0 Published
Investor FAQ BANX vs ACAD Key Questions & Quantitative Answers
As of Nov 20, 2026, ArrowMark Financial Corp. (BANX) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (39.5/100 SELL vs. 44.8/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. BANX trades at $18.79 (14.6x Forward P/E, 75.4% operating margin) versus ACAD at $17.11 (15.8x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. BANX 39.5/100 SELL), BANX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (75.4% vs. 10.2% operating margin) and revenue trajectory (-0.2% vs. +22.8% YoY). Technical & Structure Timing Caution: BANX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACAD leads the Growth & Scale pillar: BANX posts -0.2% YoY revenue growth and -58.1% YoY earnings growth on $27M TTM revenue (100.0% gross margin, 75.4% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, BANX generates $27M in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, BANX deploys 24.6% of Rev ($6.5M) (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.
ACAD screens cheaper on headline valuation multiples. BANX trades at 14.6x Forward P/E, 17.7x Trailing P/E, N/M PEG, and 6.9x EV/Revenue (unreported cash flow margin), whereas ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BANX (7.4% ROE) versus ACAD (31.4% ROE) capital efficiency.
In options market volatility and institutional positioning, BANX carries 80.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 12% Vol realized risk). By comparison, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.